Skip to main navigation
Menu
Main navigation
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2025
GRx+Biosims 2024
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action
Search
Close
Breadcrumb
Association for Accessible Medicines
Resources
Resources
Share
Find up-to-date information on generics and biosimilars
Filter Resources
Issues
Biosimilar User Fee Act (BsUFA)
Biosimilars
Complex Generics
Drug Approval Process (GDUFA)
Drug Prices
Drug Shortages
Generic Drug Labeling
Generic Supply Chain
IP Issues
Low Income Subsidies (LIS in Part D)
Medicaid
Medicare
NAFTA
Patent Reform
Patient Stories
Pharmaceutical Waste Take Back
Preventing Drug Abuse
Quality
REMS/Sample Acquisition Remedies
State Initiatives
Tariffs
Trade
Transparency
User Fees
Resource Type
Blog
Amicus Brief
Press Release
Infographic
Video
Report
Fact Sheet
Presentation
Fact Sheet
Oct 26, 2017
| Erica Klinger
AAM Issue Brief: Medicaid Generics Penalty
Blog
Oct 20, 2017
| Allen Goldberg
AAM Tells Senate: Generics Are Solution to High Drug Prices
Amicus Brief
Oct 20, 2017
| Erica Klinger
OIL STATES ENERGY SERVICES, LLC, PETITIONER v. GREENE’S ENERGY GROUP, LLC, ET AL.
Infographic
Oct 20, 2017
| Erica Klinger
Allergan Deal - The Latest Ploy
Fact Sheet
Oct 17, 2017
| Erica Klinger
AAM Amicus Brief - Oil States
Blog
Oct 16, 2017
| Rachel Schwartz
The Generic Drug Supply Chain
Fact Sheet
Oct 13, 2017
| Erica Klinger
Introduction to the Generic Drug Supply Chain
Report
Oct 12, 2017
| Erica Klinger
AAM White Paper: Renting Tribal Immunity to Evade IPR Review of Pharmaceutical Patents
Blog
Oct 10, 2017
| Erica Klinger
Health Care Orgs Urge Congress to Take Close Look at Allergan Deal
Press Release
Oct 10, 2017
| Rachel Schwartz
California SB 17 Signed Into Law
Press Release
Sep 29, 2017
| Rachel Schwartz
AAM Statement on Federal District Court Ruling on HB 631
Blog
Sep 22, 2017
| Erica Klinger
What’s the Difference Between Generics and Brand-Name Drugs?
Load More
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Advocacy
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Access! 2025
GRx+Biosims 2024
Resources
All Resources
Drug Shortages White Paper
2023 Savings Report
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action